Intervention A: Diet
Behavioralsubjects visit the dietitian at week 0, 1, 2, 6, 10 and 13 for dietary advice
Other names: very low calorie diet based on Modifast meal replacers.
NCT Number: NCT02196350
The study aims to assess the impact of the P4 approach on established markers of glucose metabolism in type 2 diabetics.
Secondary objectives are examination of the changes in physical characteristics, quality of life and the indices for beta cell function, hepatic insulin resistance and muscle insulin resistance .
Looking for future studies?
Notify Me30 year–80 year
All sexes
Interventional
Not applicable
Huisartsenpraktijk Elsbroek, Hillegom, South Holland, Netherlands
This study will be a proof-of-principle exploratory study. Subjects in the P4 program will receive a personalized diagnosis and treatment. After investigation of the status of the different organs involved in diabetes (liver, muscle, pancreas), subjects in the P4 group are divided into 3 subgroups. Each subgroup receives a personalized lifestyle advice. This lifestyle advice may comprise different interventions, i.e. very low calorie diet, low calorie diet, strength training, endurance training. Dependent on the type of intervention, these interventions will be supervised by a dietitian or physiotherapist.
All subjects will visit a central study center 5 times during the study and 3 times during follow-up. During these visits physical measures will be taken and data will be collected by the general practitioner assistant.
After the three month intervention period the subjects will return to usual care via the general practitioner.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Fasting glucose >6.9 mmol/l on two different days or one measurement of non-fasting glucose >11.0 mmol/l in combination with symptoms of hyperglycemia
Exclusion criteria
subjects visit the dietitian at week 0, 1, 2, 6, 10 and 13 for dietary advice
Other names: very low calorie diet based on Modifast meal replacers.
subjects visit the physiotherapist three times weekly; subjects visit the dietitian at week 0, 1, 2, 6, 10 and 13 for dietary advice.
subjects visit the physiotherapist three times weekly; subjects visit the dietitian at week 0, 1, 2, 6, 10 and 13 for dietary advice.
Other names: very low calorie diet based on Modifast meal replacers.
Time frame: In-study at week 0 (baseline) and 13 (end of study); follow-up after 6, 12 and 24 months
Changes in primary outcome measures will be determined by using a mixed model
Time frame: In-study at week 0 (baseline) and 13;
2h glucose will be measured after Oral Glucose Tolerance Test (OGTT). Changes in primary outcome measures will be determined by using a mixed model
Time frame: In-study at week 0 (baseline) and 13 (end of study); follow-up after 6, 12 and 24 months
After 8 hour fasting. Changes in primary outcome measures will be determined by using a mixed model.
Time frame: end of study (after 13 weeks)
normoglycemia is determined by fasting blood glucose level of less than 6.1 mmol/L
Time frame: screening; in-study at week 0, 4, 8 and 13; during follow up after 6, 12 and 24 months
measured by the general practitioner assistant
Time frame: screening; in-study at week 0, 4, 8 and 13; during follow up after 6, 12 and 24 months
measured by the general practitioner assistant
Time frame: screening; in-study at week 0, 4, 8 and 13; during follow up after 6, 12 and 24 months
measured by general practitioner assistant
Time frame: screening; in-study at week 0, 4, 8 and 13; during follow up after 6, 12 and 24 months
measured by general practitioner assistant
Time frame: screening; in-study at week 0 and 13;
at week 0 and 13 the indices will be calculated from Oral glucose tolerance test data.
Blood will be collected at the blood collection centre in Hillegom
Time frame: in-study at week 0, 13; during follow-up at 6, 12 and 24 months
established by comparing baseline values with end of study values for food intake and physical activity as measured by a Lifestyle-questionnaire
Time frame: in-study at week 0, 13; during follow-up at 6, 12 and 24 months
Time frame: in-study at week 0, 13; during follow-up at 6, 12 and 24 months
Time frame: screening; in-study at week 0 and 13;
at week 0 and 13 the indices will be calculated from Oral glucose tolerance test data.
Blood will be collected at the blood collection centre in Hillegom
Time frame: screening; in-study at week 0 and 13;
at week 0 and 13 the indices will be calculated from Oral glucose tolerance test data.
Blood will be collected at the blood collection centre in Hillegom
W.J. Pasman
Other
The Impact of the P4 Approach, Preventive, Predictive, Personalized and Participatory in Newly Diagnosed Type 2 Diabetics in Hillegom
Acronym: P4P-Hillegom
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05929079
Apnea, Body Weight
Anniston, Alabama, United States
View Trial DetailsNCT06649344
Diabetes Mellitus, Diabetes Mellitus, Type 2
Tianjin, Tianjin Municipality, China
View Trial DetailsNCT07732218
Diabetes Mellitus, Diabetes Mellitus, Type 2
Peshawar, Khyber Pakhtunkhwa, Pakistan
View Trial DetailsNCT05351359
Diabetes Mellitus, Diabetes Mellitus, Type 2
Prague, Czechia
View Trial Details